

used for one of the first 10 chemical risk evaluations conducted under amended TSCA.

- 1,4-Dioxane concentrations in surface water were modeled based on multiple upstream sources, including releases from facilities and publicly owned treatment works and down-the-drain releases. In addition, EPA compared the modeled concentrations to drinking water monitoring data for community water systems. This approach to considering the contribution of multiple sources to drinking water exposures is novel. EPA has not previously considered multiple sources of releases when estimating exposure concentrations in surface water for a chemical risk evaluation under TSCA.

b. Groundwater

- 1,4-Dioxane concentrations in groundwater were modeled for two disposal pathways by applying the Delisting Risk Assessment Software (DRAS) model in a novel way. DRAS is a multi-pathways model developed by the EPA that calculates the potential human health risks associated with disposing of a specific facility's given waste stream in a landfill or surface impoundment. (See U.S. EPA. (2020). Hazardous Waste Delisting Risk Assessment Software Version 4. Lenexa, KS: EPA Region 6. <https://www.epa.gov/hw/hazardous-waste-delisting-risk-assessment-software-dras>.) DRAS was specifically designed to address the Criteria for Listing Hazardous Waste. The 2023 Draft Supplement to the 1,4-Dioxane Risk Evaluation presents a novel application of this model and the first application in a TSCA chemical risk evaluation. Specifically, EPA compared the modeled concentrations to monitoring data from groundwater contaminations around the nation to consider if they are within a reasonable range.

EPA is also seeking review of the overall synthesis of the results of these novel methodologies and the integration of the results into the 1,4-Dioxane Risk Evaluation. Feedback from this review will be considered in the development of the final supplement to the 1,4-dioxane risk evaluation. In addition, SACC reviewer feedback may help refine EPA's methods for conducting release assessments and evaluating general population exposures in risk evaluations of other chemicals under TSCA.

III. Virtual Public Meeting of the SACC

A. What is the purpose of this public meeting?

The purpose of the 4-day virtual public meeting is the SACC peer review of the methodologies that have not been previously peer reviewed and are utilized in the 2023 Draft Supplement. Feedback from this review will be considered in the development of the final Supplement to the Risk Evaluation for 1,4-Dioxane. In addition, SACC reviewer feedback may help refine EPA's methods for conducting release assessments and evaluating general population exposures in risk evaluations of other chemicals under TSCA.

EPA intends to provide a meeting agenda for each day of the meeting, and as needed, may provide updated times for each day in the meeting agenda that will be posted in the docket and on the SACC website.

B. How can I access the documents submitted for review to the SACC?

The 2023 Draft Supplement and related documents, including background documents, related supporting materials, and draft charge questions provided to the SACC, are available in the docket. As additional background materials become available and are provided to the SACC, EPA will include those additional background documents (e.g., SACC members and consultants participating in this meeting and the meeting agenda) in the docket. All of these documents will be available through <https://www.regulations.gov> (docket ID No. EPA-HQ-OPPT-2022-0905) and through links on the SACC website at <https://www.epa.gov/tsca-peer-review>.

After the public meeting, the SACC will prepare meeting minutes and a final report document summarizing its recommendations to the EPA. This document will also be available in the docket and the SACC website.

C. How can I provide comments for the SACC's consideration?

To ensure proper receipt of comments it is imperative that you identify docket ID No. EPA-HQ-OPPT-2022-0905 in the subject line on the first page of your comments and follow the instructions in Unit I.D. and in this unit.

1. Written Comments

The Agency encourages written comments for this meeting be submitted by the deadlines set in the **DATES** section of this document and following the instructions in this document.

2. Oral Comments

The Agency encourages each individual or group wishing to make brief oral comments to the SACC during the peer review virtual public meeting to follow the registration instructions that will be announced on the SACC website by mid-August of 2023. Oral comments before the SACC during the peer review virtual public meeting are limited to 5 minutes. In addition, each speaker should submit a written copy of their oral comments and any supporting materials (e.g., presentation slides) to the DFO prior to the meeting for distribution to the SACC by the DFO.

D. How can I participate in the virtual public meeting?

The virtual public meeting will be held via a webcast platform such as "Zoomgov.com" and audio teleconference. You must register online to receive the webcast meeting link and audio teleconference information. Please follow the registration instructions that will be announced on the SACC website.

Authority: 15 U.S.C. 2625(o); 5 U.S.C 10.

Dated: July 3, 2023.

Michal Freedhoff,

Assistant Administrator, Office of Chemical Safety and Pollution Prevention.

[FR Doc. 2023-14445 Filed 7-7-23; 8:45 am]

BILLING CODE 6560-50-P

EXPORT-IMPORT BANK

Sunshine Act Meetings; Notice of an Open Meeting of the Board of Directors of the Export-Import Bank of the United States

TIME AND DATE: Thursday, July 13, 2023 at 10:30 a.m.

PLACE: The meeting will be held via teleconference.

STATUS: The meeting will be open to public observation for Item Numbers 1 and 2.

MATTERS TO BE CONSIDERED:

1. Appointment of EXIM Advisory Committee for 2023-24
2. Appointment of EXIM Sub-Saharan Africa Advisory Committee for 2023-24

CONTACT PERSON FOR MORE INFORMATION:

Joyce B. Stone (202-257-4086). Members of the public who wish to attend the meeting via teleconference should register via using the link below: https://teams.microsoft.com/registration/PAFTuZHmK2Zb1GDkIVfJw,pHLqbjVTrkuy_9KepKN6dQ,MfTnLzltSEGI6EQECd

15iQ,pMjXbySokyRw_wqUuLA
Eg,WdIf0e96Hkiy0Gzjkw_hq_
Q.P3wA84Pgo0WSW3bvGot
KOA?mode=read&tenantId=b953013c-
c791-4d32-996f-518390854527 by noon
Wednesday, July 12, 2023. Individuals
will be directed to a Webinar
registration page and provided call-in
information.

Joyce B. Stone,

Assistant Corporate Secretary.

[FR Doc. 2023-14588 Filed 7-6-23; 11:15 am]

BILLING CODE 6690-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-2438]

Medical Imaging Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Medical Imaging Drugs Advisory Committee. The general function of the committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

DATES: The meeting will be held on August 1, 2023, from 12 p.m. to 5 p.m. Eastern Time.

ADDRESSES: All meeting participants will be heard, viewed, captioned, and recorded for this advisory committee meeting via an online teleconferencing and/or video conferencing platform. Answers to commonly asked questions about FDA advisory committee meetings may be accessed at: <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm>.

FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2023-N-2438. Please note that late, untimely filed comments will not be considered. The docket will close on July 31, 2023. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 31, 2023. Comments received by mail/hand delivery/courier (for written/

paper submissions) will be considered timely if they are received on or before that date.

Comments received on or before July 25, 2023, will be provided to the committee. Comments received after that date will be taken into consideration by FDA. In the event that the meeting is canceled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.

You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand Delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA-2023-N-2438 for "Medical Imaging Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments."

Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." FDA will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify the information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

FOR FURTHER INFORMATION CONTACT: Rhea Bhatt, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-2894, email: MIDAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the **Federal Register** about last-minute modifications that impact a previously